Characterization of time toxicity in older patients with metastatic breast cancer

被引:3
作者
Atre, Swarali Y. [1 ]
Soulos, Pamela R. [2 ]
Kuderer, Nicole M. [3 ]
Gross, Cary P. [2 ,4 ]
Baum, Laura V. M. [5 ]
Dinan, Michaela A. [1 ]
Lustberg, Maryam B. [5 ]
机构
[1] Yale Univ, Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06520 USA
[2] Yale Sch Med, Canc Outcomes Publ Policy & Effectiveness Res COPP, New Haven, CT USA
[3] Adv Canc Res Grp, Seattle, WA USA
[4] Yale Sch Med, Dept Med, Sect Gen Med, New Haven, CT USA
[5] Yale Sch Med, Dept Internal Med, New Haven, CT USA
关键词
Time costs; Breast cancer; Geriatric oncology; Cancer treatment; GERIATRIC ASSESSMENT; WOMEN; BURDEN; SPENT; HOME;
D O I
10.1007/s10549-024-07379-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeRecognizing that receiving healthcare can be time intensive and burdensome, time toxicity has been conceptualized as the time spent by patients seeking healthcare. This study investigates the association between age at diagnosis and time toxicity for patients with Metastatic Breast Cancer (MBC) and identifies major components of care that confer the greatest time toxicity.MethodsWe conducted a retrospective cohort study among patients with MBC aged 67 or older using the SEER-Medicare database. We assessed time toxicity using the number of encounter days patients interacted with the healthcare system per 100 days, within the first year of starting cancer treatment. We used a Poisson model to analyze the association between age and encounter days, adjusting for clinical and sociodemographic factors. We stratified the mean encounter days for each age cohort by treatment types.FindingsThe final sample included 2949 patients; 51.4% were between 70 and 79 years old, and 81.3% were white. Although unadjusted analysis showed an association between older age and more encounter days (Rate Ratio (RR) 1.12; 95% CI 1.02, 1.22), there was no significant association after adjusting for comorbidities and treatment type. Patients with more than three comorbidities had significantly higher encounter days compared to those without comorbidities [RR 1.36 (95% CI 1.26, 1.46)]. Receipt of radiotherapy [RR: 1.45 95% CI (1.37, 1.54)] was associated with more encounter days compared to not receiving radiotherapy, while receipt of bone-modifying agents was associated with fewer encounter days compared to not using Bone modifying agents [RR 0.75 (95% CI 0.70, 0.79)].ConclusionOur study identified comorbidities and cancer treatment modality, including radiotherapy, as the factors affecting time toxicity in older patients with MBC. Assessment of an individual's comorbid medical conditions and types of treatment planned are crucial to understanding age-related impacts on encounter days and to support shared decision making in older patients.
引用
收藏
页码:541 / 550
页数:10
相关论文
共 37 条
[1]   Treatment burden in individuals living with and beyond cancer: A systematic review of qualitative literature [J].
Adam, Rosalind ;
Nair, Revathi ;
Duncan, Lisa I. ;
Yeoh, Esyn ;
Chan, Joanne ;
Vilenskaya, Vaselisa ;
Gallacher, Katie .
PLOS ONE, 2023, 18 (05)
[2]   Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients [J].
Aguiar-Ibanez, Raquel ;
Scherrer, Emilie ;
Grebennik, Dmitri ;
Cook, John ;
Bagga, Shalini ;
Sawhney, Baanie ;
Khandelwal, Anvi ;
Soefje, Scott A. .
BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
[3]  
[Anonymous], National Comprehensive Cancer Guidelines (Version 2.2005)
[4]  
[Anonymous], SEER MEDICARE BRIEF
[5]   Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma [J].
Bange, Erin M. ;
Doucette, Abigail ;
Gabriel, Peter E. ;
Porterfield, Florence ;
Harrigan, James J. ;
Wang, Robin ;
Wojcieszynski, Andrzej P. ;
Boursi, Ben ;
Mooney, Bethany I. ;
Reiss, Kim A. ;
Mamtani, Ronac .
JCO ONCOLOGY PRACTICE, 2020, 16 (08) :504-+
[6]  
Berger Nathan A, 2006, Trans Am Clin Climatol Assoc, V117, P147
[7]   Treatment of Older Adults with Cancer - Addressing Gaps in Evidence [J].
Bertagnolli, Monica M. ;
Singh, Harpreet .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1062-1065
[8]   Oncology nursing workforce: challenges, solutions, and future strategies [J].
Challinor, Julia M. ;
Alqudimat, Mohammad R. ;
Teixeira, Tamara O. A. ;
Oldenmenger, Wendy H. .
LANCET ONCOLOGY, 2020, 21 (12) :E564-E574
[9]   Measures of Treatment Workload for Patients With Breast Cancer [J].
Cheng, Alex C. ;
Levy, Mia A. .
JCO CLINICAL CANCER INFORMATICS, 2019, 3 :1-10
[10]  
Cheng Alex C, 2016, AMIA Annu Symp Proc, V2016, P1756